The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
Background: Polycystic ovary syndrome (PCOS) is associated with an adverse cardiovascular risk profile including a prothrombotic state. Exenatide has been shown to be effective at improving insulin sensitivity and weight loss in PCOS; therefore this study was undertaken to assess its effects on weight, endothelial function, inflammatory markers, and fibrin structure/function in overweight/obese women with PCOS. Methods: Thirty overweight/obese anovulatory women with all 3 Rotterdam criteria received exenatide 5mcg bd for 4 weeks then 10mcg bd for 12 weeks. The primary outcome was change in weight; secondary outcomes were changes in endothelial function (Reactive Hyperemia-Peripheral Arterial Tonometry (RH-PAT)), serum endothelial markers (ICAM-1, VCAM-1, E-selectin and P-selectin), change in inflammation (hsCRP), and alteration in clot structure and function (maximum absorbance (MA), and time from full clot formation to 50% lysis (LT)). Results: Twenty patients completed the study. Exenatide reduced weight 111.8±4.8kg to 108.6±4.6kg p=0.003. Serum endothelial markers changed with a reduction in ICAM (247.2±12.9 to 231.3±11.5ng/ml p=0.02), p-selectin (101.1±8.2 to 87.4±6.6 ng/ml p=0.01) and e-selectin (38.5±3.3 to 33.6±2.6 ng/ml p=0.03), without an overt change in endothelial function. Inflammation improved (CRP; 8.5±1.4 to 5.6±0.8 mmol/L p=0.001), there was a reduction in clot function (LT; 2987±494 to 1926±321s p=0.02) but not clot structure. Conclusion: Exenatide caused a 3% reduction in weight, improved serum markers of endothelial function, inflammation and clot function reflecting an improvement in cardiovascular risk indices in these women with PCOS. This suggests exenatide could be an effective treatment for obese women with PCOS.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
The Potential Implications of a PCOS Diagnosis on a Woman's Long-Term Health Using Data Linkage
Hart, R., & Doherty, D. A. (2015) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2014-3886 · Cited by 391
Exenatide Exerts a Potent Antiinflammatory Effect
Chaudhuri, A., Ghanim, H., Vora, M., Sia, C. L., Korzeniewski, K., Dhindsa, S., Makdissi, A., & Dandona, P. (2012) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2011-1508 · Cited by 284
Elkind-Hirsch, K., Marrioneaux, O., Bhushan, M., Vernor, D., & Bhushan, R. (2008) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2008-0115 · Cited by 276 · cited 7×
“The weakness of this study is the high drop-out rate which largely was due to side effects of the medication (namely nausea and vomiting), however the withdrawal rate was similar to that reported in a previous study (22) of 30%.”
BackgroundMethodResultInfluentialHorton, E. S., Silberman, C., Davis, K. L., & Berria, R. (2010) · Diabetes Care · doi:10.2337/dc09-2062 · Cited by 156
Jensterle, M., Salamun, V., Kocjan, T., Vrtacnik Bokal, E., & Janez, A. (2015) · Journal of Ovarian Research · doi:10.1186/s13048-015-0161-3 · Cited by 103
Jensterle, M., Kocjan, T., Kravos, N. A., Pfeifer, M., & Janez, A. (2015) · Endocrine Research · doi:10.3109/07435800.2014.966385 · Cited by 86
JENSTERLE, M., GORICAR, K., & JANEZ, A. (2016) · Experimental and Therapeutic Medicine · doi:10.3892/etm.2016.3081 · Cited by 56 · cited 1×
“GLP-1 analogs have shown to reduce weight (22–27), reduce hyperandrogenism (22, 27) and improve menstrual cyclicity (22, 25) in women with PCOS.”
Background
Cited by
Polycystic Ovary Syndrome: Pathophysiology and Therapeutic Opportunities
Dong, J., & Rees, D. A. (2023) · BMJ Medicine · doi:10.1136/bmjmed-2023-000548 · Cited by 123
“136 137 A meta-analysis of eight randomised controlled trials concluded that GLP-1 agonists were more effective than metformin in improving homeostasis model assessment-insulin resistance (standard mean difference −0.40, 95% confidence interval −0.74 to −0.06), abdominal circumference (−0.45, −0.89…”
InfluentialUpdate on the effects of GLP-1 receptor agonists for the treatment of polycystic ovary syndrome
Siamashvili, M., & Davis, S. N. (2021) · Expert Review of Clinical Pharmacology · doi:10.1080/17512433.2021.1933433 · Cited by 82
Jensterle, M., Herman, R., & Janež, A. (2022) · Biomedicines · doi:10.3390/biomedicines10081989 · Cited by 50
Pharmacological Approaches to Controlling Cardiometabolic Risk in Women with PCOS
Cignarella, A., Mioni, R., Sabbadin, C., Dassie, F., Parolin, M., Vettor, R., Barbot, M., & Scaroni, C. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21249554 · Cited by 36
Javed, Z., Papageorgiou, M., Madden, L. A., Rigby, A. S., Kilpatrick, E. S., Atkin, S. L., & Sathyapalan, T. (2020) · Endocrine Connections · doi:10.1530/ec-20-0173 · Cited by 24
Self-citation
Metadata
- Authors
- Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A.-M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L.
- Venue
- Frontiers in Endocrinology
- Publisher
- Frontiers Media SA
- Published
- 2019-04-02
- Volume
- 10
- Pages
- 189-189
- ISSN
- 1664-2392 (ISSN-L)
- OpenAlex
- W2925508960
- Cited by
- 33
- References
- 7
- FWCI
- 2.99
- Type
- journal article
- Language
- en
- Open access
- gold
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. https://app.cochat.ai/papers/10.3389/fendo.2019.00189
- The paper
- Dawson, A. J., Sathyapalan, T., Vince, R., Coady, A.-M., Ajjan, R. A., Kilpatrick, E. S., & Atkin, S. L. (2019). The Effect of Exenatide on Cardiovascular Risk Markers in Women With Polycystic Ovary Syndrome. Frontiers in Endocrinology. https://doi.org/10.3389/fendo.2019.00189
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.